ClinicalTrials.gg
CompletedNCT03442751Updated Jan 30, 2024Results posted

Study to Evaluate the Safety and Efficacy of Epi-on Corneal Cross-linking in Eyes With Progressive Keratoconus

A Phase 3 interventional study of Test Article A and Test Article B in Progressive Keratoconus, sponsored by Glaukos Corporation. Completed at 1 site in United States. Open to participants aged 12 Years to 55 Years. Per ClinicalTrials.gov, last updated 2024-01-30.

Sponsored by Glaukos Corporation · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
201
Allocation
Randomized
Ages
12 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 94 studies in Keratoconus with a site in United States — 27 open to participants now, 33 under way, 9 of them phase 3. Keratoconus · United States.

Enrollment
25th of 71
201 · median 147
Started
2018
with 4 others
Phase 3
23 of 94
5 open now
Registered
50th of 94
by date
Lead sponsor
8 of 94
Glaukos Corporation

Among the 94 studies in Keratoconus with a site in United States, this one is the 25th largest by enrollment of the 71 interventional ones that give a count, is one of 5 that started in 2018, is one of 23 in phase 3, and was the 50th registered.

Keratoconus

313 studies on the registry are indexed under Keratoconus; 56 are open to participants now.

Browse Keratoconus studies →

Open to participants now

27 of the 94 studies in Keratoconus with a site in United States are open now. Recruiting first, the newest first:

22 more — sign in →

All 27 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 37 Keratoconus studies recruiting now, 21 (57%) set no upper age limit and 11 (30%) stop at 75 or younger; 17 take children under 18; 15 take healthy volunteers.

This study: 12 Years to 55 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 94 studies in Keratoconus with a site in United States, or all of them as a file.
02

Study summary

To evaluate the safety and efficacy of epithelium-on corneal collagen cross-linking (CXL) in impeding the progression of, and/or reducing corneal curvature (Kmax) in eyes with progressive keratoconus. Epithelium-on CXL uses a formulation that allows the riboflavin to penetrate the cornea without the need to remove the epithelium, the outer most layer of the cornea.

Read the detailed description

Up to 275 study eyes with progressive keratoconus will be enrolled. Study eyes will be randomized in a 2:1 ratio to receive CXL treatment or sham/control treatment.The primary efficacy endpoint is a difference of ≥ 1 diopter between treatment groups in the mean change in Kmax from baseline to Month 6.

03

Conditions studied

  • Progressive Keratoconus

Browse trials for

04

Who can participate

Ages eligible
12 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Be between 12 and 55 years of age, male or female, of any race;
  2. Provide written and sign a HIPAA form. Subjects who are under the age of 18 (or have not yet reached the age of majority per local regulations) will need to sign an assent form as well as having a parent or legal guardian sign an informed consent
  3. Ability to read English or Spanish to complete the NEI-VFQ 25 questionnaire;
  4. Willingness and ability to follow all instructions and comply with schedule for follow-up visits;
  5. For females capable of becoming pregnant, agree to have urine pregnancy testing performed prior to randomization of each study eye; must not be lactating, and must agree to use a medically acceptable form of for at least one week prior to the randomization visit, and continue to use the method for one month following the treatment. Acceptable forms for birth control are spermicide with barrier, oral contraceptive, injectable or implantable method of contraception, transdermal contraceptive, intrauterine device, or surgical sterilization of partner. For non-sexually active females, abstinence will be considered an acceptable form of birth control. Women considered capable of becoming pregnant include all females who have experienced menarche and have not experienced menopause (as defined by amenorrhea for greater than 12 consecutive months) or have not undergone successful surgical sterilization (e.g. hysterectomy, bilateral tubal ligation, or bilateral oophorectomy);
  6. Having topographic and clinical evidence of keratoconus

Exclusion criteria

Exclusion Criteria:

  1. , sensitivity or known allergy to the use of the test article(s) or their components;
  2. If female, be pregnant, nursing or planning a pregnancy or have a positive urine pregnancy test prior to the randomization or treatment of either eye or during the course of the study;
  3. Previous ocular condition (other than refractive error) in the eye to be treated that may predispose the eye for future complications.
  4. A history of delayed epithelial healing in the eye to be treated or a current condition that may interfere with or prolong epithelial healing;
  5. A history of previous corneal cross-linking treatment in the eye to be treated;
  6. Have used an drug or device within 30 days of screening or be concurrently enrolled in another investigational drug or device trial within 30 days of the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
201 participants (actual)

Study arms

  • Experimental
    Epithelium-on CXL Treatment Group

    Study eye receives Test Article A, Test Article B, and exposed to cross-linking dose of UVA light generated by the KXL medical device system

    Drug: Test Article A · Drug: Test Article B · Device: KXL medical device system

  • Sham comparator
    Sham Treatment/Control Group

    Sham eye receives Placebo and and exposed to mock dose of UVA light generated by the KXL medical device system

    Drug: Placebo · Device: KXL medical device system

Interventions

  • DrugTest Article A

    Riboflavin Ophthalmic Solution A

  • DrugTest Article B

    Riboflavin Ophthalmic Solution B

  • DrugPlacebo

    Placebo Vehicle of Test Article

  • DeviceKXL medical device system

    Mock UVA light source

  • DeviceKXL medical device system

    Cross-linking UVA light source

06

What researchers measure

Primary outcomes

  1. Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax

    Mean difference of at least 1 diopter in Kmax change from baseline to Month 6 between treatment groups

    Time frame: 6 months

Secondary outcomes

  1. Difference Between Treatment Groups in the Change From Baseline to Month 12 in Kmax

    Difference between the CXL and Sham/Control treatment groups in the change from baseline to Month 12 in Kmax

    Time frame: 12 months

07

Results

Posted Jan 30, 2024

Participant flow

Subjects were recruited at eye clinics and were required to meet inclusion/exclusion criteria prior to enrollment

Participant flow — Overall Study
MilestoneEpithelium-on CXL Treatment GroupSham Treatment/Control Group
Started15683
Month 615382
Month 121500
Completed15082
Not completed61
Withdrew: Withdrawal by subject31
Withdrew: Lost to follow-up30

Outcome measures

PrimaryDifference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax

Mean difference of at least 1 diopter in Kmax change from baseline to Month 6 between treatment groups

Time frame:
6 months
Reported as:
Least squares mean · Diopters
Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax
DioptersEpithelium-on CXL Treatment GroupSham Treatment/Control Group
Difference Between Treatment Groups in the Change From Baseline to Month 6 in Kmax-0.3 (-0.6 to -0.0)0.6 (0.2 to 1.1)
Statistical analysis
  • Epithelium-on CXL Treatment Group vs Sham Treatment/Control Group · ANCOVA · p = 0.0004 · Mean difference (net): -1.0 · 95% CI -1.5 to -0.4
SecondaryDifference Between Treatment Groups in the Change From Baseline to Month 12 in Kmax

Difference between the CXL and Sham/Control treatment groups in the change from baseline to Month 12 in Kmax

Time frame:
12 months
Reported as:
Least squares mean · Diopters
Difference Between Treatment Groups in the Change From Baseline to Month 12 in Kmax
DioptersEpithelium-on CXL Treatment GroupSham Treatment/Control Group
Difference Between Treatment Groups in the Change From Baseline to Month 12 in Kmax-0.4 (-0.7 to -0.2)0.7 (0.3 to 1.1)
Statistical analysis
  • Epithelium-on CXL Treatment Group vs Sham Treatment/Control Group · ANCOVA · p = <0.0001 · Mean difference (net): -1.1 · 95% CI -1.6 to -0.6

Adverse events

Collected over 12 months for the Epithelium-on CXL Treatment Group and 6 months for the Sham Treatment/Control Group. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Ocular: Epithelium-on CXL Treatment Group0/189 (0%)1/189 (0.5%)170/189 (89.9%)
Ocular: Sham Treatment/Control Group0/90 (0%)0/90 (0%)63/90 (70%)
Non-ocular: Epithelium-on0/118 (0%)2/118 (1.7%)1/118 (0.8%)
Non-ocular: Sham Treatment/Control0/45 (0%)0/45 (0%)0/45 (0%)
Non-ocular: Epithelium-on and Sham Treatment0/38 (0%)1/38 (2.6%)2/38 (5.3%)
Most frequent serious events
Most frequent serious events
EventOcular: Epithelium-on CXL Treatment GroupOcular: Sham Treatment/Control GroupNon-ocular: Epithelium-onNon-ocular: Sham Treatment/ControlNon-ocular: Epithelium-on and Sham Treatment
Uterine leiomyomaReproductive system and breast disorders0/1890/900/1180/451/38
Urinary tract infectionRenal and urinary disorders——1/1180/450/38
Kidney infectionRenal and urinary disorders—0/901/1180/450/38
Depression suicidalPsychiatric disorders0/1890/901/1180/450/38
Cataract subcapsularEye disorders1/1890/900/1180/450/38
Retinal detachmentEye disorders1/1890/900/1180/450/38
Corneal opacityEye disorders1/1890/900/1180/450/38
Most frequent other events
Showing 10 of 22
Most frequent other events
EventOcular: Epithelium-on CXL Treatment GroupOcular: Sham Treatment/Control GroupNon-ocular: Epithelium-onNon-ocular: Sham Treatment/ControlNon-ocular: Epithelium-on and Sham Treatment
Conjunctival hyperaemiaEye disorders115/18925/900/1180/450/38
Corneal opacityEye disorders77/18911/900/1180/450/38
PhotophobiaEye disorders73/18912/900/1180/450/38
Punctate keratitisEye disorders66/18927/900/1180/450/38
Eye painEye disorders61/1895/900/1180/450/38
Eye irritationEye disorders59/1897/900/1180/450/38
Lacrimation increasedEye disorders36/1891/900/1180/450/38
Corneal epithelium defectEye disorders28/1890/900/1180/450/38
Eyelid oedemaEye disorders27/1892/900/1180/450/38
Corneal striaeEye disorders26/1894/900/1180/450/38

Baseline characteristics

Subjects with progressive keratoconus in at least one eye (study eye). Subjects may contribute more than one eye if both eyes qualify. Eyes vs. subjects were randomized to the treatment arms.

Age, Continuous
Age, Continuous(years)Epithelium-on CXL Treatment GroupSham Treatment/Control GroupTotal
Mean30.0 ± 9.7529.5 ± 9.6730.0 ± 9.9
Sex/Gender, Customized
Sex/Gender, Customized(participants)Epithelium-on CXL Treatment GroupSham Treatment/Control GroupTotal
Male10955139
Female472862
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Epithelium-on CXL Treatment GroupSham Treatment/Control GroupTotal
Ethnicity: Hispanic or Latino286836
Ethnicity: Not Hispanic or Latino12815165
Race/Ethnicity, Customized
Race/Ethnicity, Customized(participants)Epithelium-on CXL Treatment GroupSham Treatment/Control GroupTotal
Race: Asian345
Race: Black or African American271836
Race: Native Hawaiian or Other Pacific Islander313
Race: White11254142
Race: Other11615
Mean Kmax (D)
Mean Kmax (D)(Diopters)Epithelium-on CXL Treatment GroupSham Treatment/Control GroupTotal
Mean59.4 ± 9.159.3 ± 9.159.4 ± 9.1
08

Study locations

1 site
  • Ophthalmic Consultants of Boston
    Waltham, Massachusetts 02451, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2018 to primary completion in Nov 2019, 18 months.

Results were first posted in Jan 2024, 4 years 2 months after primary completion. A results delay was requested in Dec 2020.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2018
First posted
Feb 22, 2018
StartActual
Apr 6, 2018
Primary completionActual
Nov 1, 2019
CompletionActual
Aug 10, 2020
Results delay requested
Dec 16, 2020
Results first posted
Jan 30, 2024
Last update
Jan 30, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 30, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03442751
Responsible party
Sponsor
First posted
Feb 22, 2018
Start date
Apr 6, 2018
Primary completion
Nov 1, 2019
Completion
Aug 10, 2020
Results posted
Jan 30, 2024
Last update
Jan 30, 2024

Study contacts

Valerie Smith
study director · Glaukos Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion